Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results


Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC

Read more here:
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results

Related Posts